Abstract
The aim of this study was to investigate the effect of previous exposure to CsA on the expression of RANK and bone loss in experimental periodontitis induced in rats. Forty rats were divided into four groups as follows: Control (CON); Cyclosporine A (CsA), with daily doses of 10 mg/Kg of CsA; Ligature (LIG), with a ligature around the upper right second molar on day 30; and Ligature + CsA (CsAL). Sixty days later, the animals were sacrificed and samples removed for histomorphometric and immunohistochemical analysis of bone resorption, bone density and RANK expression. There was no significant influence of bone resorption on the application of CsA. LIG Group (735.88 ± 121.82) had significantly higher bone resorption (p = 0.01) than CON Group (569.13 ± 89.76), and CsAL Group (759.38 ± 198.23) also had significantly higher bone resorption (P = 0.001) than CsA Group (410.90 ± 105.95). Bone density in the CsA Group (87.49 ± 4.07) was lower than that of CON Group (92.42 ± 2.27) and similar to that of LIG Group (91.85 ± 3.91). CsAL Group (79.41 ± 3.81) showed the lowest density compared to the other groups. RANK did not differ between the groups. The prior exposure to CsA had no influence on the expression of RANK or bone resorption.
Highlights
Cyclosporine A (CsA) is widely used as an immunosuppressive drug in patients who received transplants
This study has investigated bone loss in ligature-induced periodontitis in immunosuppressed rats by using CsA
Changes in the metabolism of bone tissue caused by CsA represent an adverse effect of this drug and may be a possible risk factor for periodontal disease, contributing to the beginning, progression and repair of periodontal disease (Liang et al, 2008; Jayasheela et al, 2013)
Summary
Cyclosporine A (CsA) is widely used as an immunosuppressive drug in patients who received transplants. Unwanted side effects associated with the use of CsA were already described in the literature, such as dyslipidemia, neuro and nephron-toxicity, hypertension, gingival overgrowth, osteopenia and osteoporosis. These side effects are associated with the prolonged therapy with high doses and concomitant use with other drugs. There is controversy about the effects of CsA on biological events of bone remodeling (Fu et al, 2001; Spolidório et al, 2001; Spolidório et al, 2004; Wada et al, 2006)
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
